drugset / Trial / NCT07241546

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

NCT07241546 ↗

Phase 2 Recruiting 36 enrolled Arrowhead Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Timeline

Start
2026-03-30
Primary completion
2027-12
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ARO-RAGE Unknown — Inhaled

Indications